Most Liquid Health Management Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1REGN Regeneron Pharmaceuticals
7.02 B
(0.06)
 2.00 
(0.11)
2CAH Cardinal Health
4.04 B
 0.17 
 1.09 
 0.18 
3ME 23Andme Holding Co
410.89 M
(0.11)
 6.24 
(0.72)
4DH Definitive Healthcare Corp
347.87 M
(0.07)
 5.92 
(0.43)
5NEOG Neogen
347.71 M
(0.19)
 2.57 
(0.49)
6VALN Valneva SE ADR
336.22 M
 0.20 
 5.20 
 1.01 
7TFX Teleflex Incorporated
292.03 M
(0.10)
 3.15 
(0.31)
8GNFT Genfit
209.12 M
 0.01 
 3.26 
 0.03 
9ABOS Acumen Pharmaceuticals
189.91 M
(0.15)
 3.85 
(0.58)
10INBX Inhibrx
176.38 M
 0.01 
 3.41 
 0.04 
11ALVO Alvotech
128.44 M
(0.06)
 2.04 
(0.11)
12ANRO Alto Neuroscience,
203.14 M
(0.11)
 5.22 
(0.58)
13APGE Apogee Therapeutics, Common
109.87 M
(0.04)
 4.35 
(0.19)
14TCRX Tscan Therapeutics
125.6 M
(0.19)
 4.28 
(0.82)
15SMMT Summit Therapeutics PLC
121.97 M
 0.04 
 5.36 
 0.20 
16TELO Telomir Pharmaceuticals, Common
1.53 M
 0.00 
 5.61 
 0.01 
17CPRX Catalyst Pharmaceuticals
220.79 M
 0.07 
 3.20 
 0.24 
18RDNT RadNet Inc
99.17 M
(0.21)
 2.79 
(0.58)
19ARDX Ardelyx
90.62 M
 0.06 
 4.53 
 0.26 
20TOVX Theriva Biologics
52.27 M
(0.05)
 7.41 
(0.33)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).